What\'s new?
============

This study is the first to highlight the importance of using both eyes in assessing Quality of Life in diabetic macular oedema using a weighting between the better- and worse-seeing eyes.

Introduction
============

Diabetes is estimated to be increasing worldwide from 382 million in 2013 to 592 million in 2035 [@b1], and is a major cause of morbidity worldwide [@b2], with the incidence of diabetic retinopathy increasing in parallel. In people with diabetic retinopathy, the major cause of moderate vision loss is diabetic macular oedema, which can progress to cause increased visual impairment and eventual blindness, as defined by the World Health Authority definition of visual acuity (VA) ≤ 6/60 (log MAR ≥ 1.00) in the better-seeing eye [@b3].

The health-related quality of life (HRQoL) of people with diabetic macular oedema is adversely affected at all stages of the disease [@b4],[@b5]. Our current analysis was designed to use the baseline Quality of Life (QoL) EQ--5D--3L and NEI--VFQ 25 data and the VA data from a recent clinical trial [@b6] to determine the impact of the level of vision in the better- and worse-seeing eye on QoL, as a relative weighting between the vision in the two eyes as had previously been suggested in people with macular degeneration by Pleil *et al*. [@b7].

The European Quality of Life (EuroQol) Group EQ--5D--3L [@b8] is a generic instrument for describing and valuing health. It consists of two parts, the first having five domains from which the responses are combined using an algorithm to provide a single index value using MVH weights [@b9], for the health status of the individual; a score of 1 corresponds to perfect health, and a score of 0 corresponds to being dead. The second part of the tool is a visual analogue scale.

The second questionnaire was the National Eye Institute-Visual Functioning Questionnaire 25(NEI--VFQ 25) [@b10]. It comprises 25 items to assess the difficulty of visual symptoms or day-to-day activities with 11 vision-related domains. All responses, apart from the general health question, are combined to provide a single composite score.

Methods
=======

This retrospective analysis used baseline data from participants enrolled in the multicentre, Phase 2/3, randomized, sham-controlled, double-masked, 2-year, comparative trial (NCT 00605280) [@b11] in ophthalmology treatment centres in the USA, Canada, Australia, Europe, South America and India. Participants were ≥ 18 years of age with Type 1 or Type 2 diabetes and diabetic macular oedema involving the centre of the macula not associated with ischaemia. Participants were administered intravitreal injections of pegaptanib sodium 0.3 mg or sham injection every 6 weeks for up to 2 years. Details of inclusion and exclusion criteria, trial design and results can be obtained from the original publication of this trial [@b11].

Patient HRQoL was determined using the two separate instruments, the EQ--5D--3L and the NEI--VFQ 25 described above. Both instruments were administered to participants between the screening and baseline visit. In India, the two questionnaires were administered in the clinic by trained study personnel using paper-based versions which were faxed to the call centre for data entry onto the system. In all other centres, the questionnaires were administered in the participants' local language by trained interviewers at a call centre and data were entered directly into a database.

In the trial, baseline VA was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study (ETDRS) Log MAR charts. Distance VA was expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 94, where higher ETDRS scores represented better vision.

Linear regression models with QoL score from each vision-related domain and with the EQ--5D index value as the dependent variables were fitted using linear and quadratic terms in the terms of the better and worse eye, age and gender, and were adjusted for number of concurrent conditions, ethnicity and level of diabetes control. Stepwise model selection procedures were used. All analyses were carried out using SAS v. 9.1.

Results
=======

The countries of origin of the 326 participants were: USA (50), Canada (7), Australia (5), South America (10), India (27) and Europe (188), including Austria (9), Czech Republic (69), Denmark (4), France (33), Germany (26), UK (7), Italy (25), the Netherlands (3), Portugal (10) and Switzerland (2).

Of the 326 participants, 37 did not have a composite VFQ result, i.e. they did not complete every section of the VFQ 25, and hence results are available for 289 participants in this trial with diabetic macular oedema, 55% were male and 82% were Caucasian (see Table[1](#tbl1){ref-type="table"}). The range of VA in the better-seeing eye was 35--94 letters, median interquartile (IQR) range 69 (62--77) letters. The range of VA in the worse-seeing eye was 0--70, 56 (46--63) letters. The correlation coefficient (*r*^2^) between VA in the better and worse eyes was 0.57 (*P* \< 0.0001).

###### 

Characteristics of the study population

                                                                                                            *N*           \%
  ------------------------------------------------------------------------------ -------------------------- ------------- ------
  Gender                                                                         Men                        160           55.4
  Women                                                                          129                        44.6          
  Ethnicity                                                                      Caucasian                  237           82.0
  Asian                                                                          28                         9.7           
  Hispanic                                                                       13                         4.5           
  Black                                                                          7                          2.4           
  Other                                                                          4                          1.4           
  Diabetes                                                                       Type 1                     26            9.0
  Type 2                                                                         263                        91.0          
  Smoker                                                                         No                         20            6.9
  Yes                                                                            269                        93.1          
  HbA1c                                                                          \< 60 mmol/mol (\< 7.6%)   135           46.7
  ≥ 60 mmol/mol≥ 7.6%)                                                           154                        53.3          
  Body Mass Index (weight (kg)/(height (m)^2^)[†](#tf1-1){ref-type="table-fn"}                              29.8 (5.5)     
  Systolic blood pressure (mmHg)[†](#tf1-1){ref-type="table-fn"}                                            138 (14)       
  Diastolic blood pressure (mmHg)[†](#tf1-1){ref-type="table-fn"}                                           78 (9)         
  Visual acuity (ETDRS letters) in better eye[\*](#tf1-1){ref-type="table-fn"}                              69 (61--77)    
  Visual acuity (ETDRS letters) in better eye[†](#tf1-1){ref-type="table-fn"}                               69.1 (11.7)    
  Visual acuity (ETDRS letters) in worse eye[\*](#tf1-1){ref-type="table-fn"}                               56 (46--63)    
  Visual acuity (ETDRS letters) in worse eye[†](#tf1-1){ref-type="table-fn"}                                52.4 (13.4)    
  Number illnesses recorded[\*](#tf1-1){ref-type="table-fn"}                                                4 (2--6)       

Median (25th to 75th centiles); †Mean ([sd]{.smallcaps}).

The results of the regression analyses (Table[2](#tbl2){ref-type="table"}) show that the proportion of variance in QoL scores explained by age group, gender, HbA~1c~ group and ethnicity, although statistically significant, was not large (highest *r*^2^ = 0.14 for driving).

###### 

Regression analyses relating Quality of Life scores to vision

                        Incremental *r*^2^ beyond age group, gender, HbA~1c~ group, race                                                                                                                  
  --------------------- ------------------------------------------------------------------ ------- ------ ------- ------- ----------- ------- ----------- ------- ----------- ------- ----------- ------- -----------
  General health        289                                                                41.1    22.5   0.040   0.031   0.0027      0.019   0.0197      0.033   0.0018      0.032   0.0021      0.030   0.0027
  General vision        289                                                                54.3    17.8   0.017   0.137   \< 0.0001   0.098   \< 0.0001   0.152   \< 0.0001   0.152   \< 0.0001   0.148   \< 0.0001
  Ocular pain           289                                                                78.8    22.9   0.061   0.002   0.4884      0.007   0.1469      0.003   0.3195      0.004   0.2479      0.005   0.2134
  Near activities       289                                                                57.9    23.7   0.029   0.158   \< 0.0001   0.094   \< 0.0001   0.169   \< 0.0001   0.164   \< 0.0001   0.157   \< 0.0001
  Distant activities    289                                                                63.5    24.7   0.022   0.192   \< 0.0001   0.109   \< 0.0001   0.202   \< 0.0001   0.195   \< 0.0001   0.185   \< 0.0001
  Vision-specific                                                                                                                                                                                         
   Social functioning   289                                                                79.3    23.2   0.052   0.128   \< 0.0001   0.079   \< 0.0001   0.138   \< 0.0001   0.135   \< 0.0001   0.129   \< 0.0001
   Mental health        289                                                                55.9    28.3   0.089   0.098   \< 0.0001   0.068   \< 0.0001   0.109   \< 0.0001   0.108   \< 0.0001   0.105   \< 0.0001
   Role difficulties    289                                                                54.4    28.3   0.059   0.080   \< 0.0001   0.080   \< 0.0001   0.097   \< 0.0001   0.102   \< 0.0001   0.102   \< 0.0001
   Dependency           289                                                                68.4    31.3   0.109   0.094   \< 0.0001   0.088   \< 0.0001   0.113   \< 0.0001   0.117   \< 0.0001   0.117   \< 0.0001
   Driving              148                                                                67.9    23.3   0.140   0.115   \< 0.0001   0.070   0.0006      0.127   \< 0.0001   0.127   \< 0.0001   0.123   \< 0.0001
   Colour vision        287                                                                86.2    21.9   0.024   0.022   0.0112      0.030   0.0032      0.030   0.0034      0.033   0.0021      0.034   0.0017
   Peripheral vision    288                                                                71.4    25.9   0.023   0.084   \< 0.0001   0.095   \< 0.0001   0.106   \< 0.0001   0.114   \< 0.0001   0.116   \< 0.0001
   Composite            289                                                                66.2    19.2   0.060   0.160   \< 0.0001   0.135   \< 0.0001   0.186   \< 0.0001   0.190   \< 0.0001   0.188   \< 0.0001
   EQ5D                 289                                                                0.738   0.2    0.071   0.019   0.0160      0.033   0.0015      0.027   0.0038      0.032   0.0019      0.033   0.0014

Some items, e.g. driving have a response choice that indicates that the respondent does not perform the activity for reasons unrelated to vision. If a respondent selects this choice, the answer is treated as missing and an average of the remaining items is calculated. This is the reason for the reduced number in some domains.

Table[2](#tbl2){ref-type="table"} shows the relative contributions of the better- and worse-seeing eyes to the QoL scores, alone and in combination of better seeing/worse seeing 0.75/0.25, then 0.60/0.40 and the last being 0.50/0.50. These combinations were chosen with higher contributions in the better-seeing eye because *r*^2^ values for the NEI--VFQ 25 in Table[2](#tbl2){ref-type="table"} show that the contribution of the worse eye is less than that of the better-seeing eye.

There was a relationship (*P* = 0.016) between EQ--5D--3L scores and VA in the better-seeing eye, for those with a VA in the better eye of \< 60 letters, the median EQ--5D--3L score was 0.73 (0.59--0.81), and for those with a VA of ≥ 80 in the better-seeing eye, the median EQ--5D--3L score was 0.80 (0.69--0.94).

By using the QoL data, the current analysis did not show a strong correlation (levels of 0.027--0.033) with the EQ--5D--3L.

For the NEI--VFQ 25, there was no relationship between VA in either eye and ocular pain. There was a stronger correlation between visual loss and other QoL domains (e.g. distance 0.185--0.202 and near 0.157--0.169) and composite scores (0.186--0.19) using the NEI--VFQ 25. This links most closely to the visual loss in the better-seeing eye, but there is also a correlation with the worse-seeing eye. For all other vision-related QoL domains the VA in both the better and the worse eye gave a significant increase in *r*^2^. Different combinations of VA in the better- and worse-seeing eyes show different effects on the QoL scores. For all but colour and peripheral vision, the increase was significantly larger for VA in the better than the worse-seeing eye.

For the three combinations of VA in the better- and worse-seeing eyes presented in Table[2](#tbl2){ref-type="table"}, the incremental increase in *r*^2^ was larger for combinations of VA in the better- and worse-seeing eyes than for either eye alone. The domains for which this was greatest were for the composite scores of peripheral vision, role difficulties and dependency.

Discussion
==========

In 2002, Brown *et al*. [@b12] reported that visual loss caused a diminution in self-assessed quality of life but did not appear to be affected by the presence of co-morbidities. However, Davidov *et al*. [@b4] found that, as well as ocular disease levels of diabetic retinopathy, patient co-morbidities lead to significant impairment of both the physical and mental components of the HRQoL. A study of the impact of laser treatment [@b13] concluded that, after a pronounced reduction of quality-of-life impacts following the first laser treatment, there was an increasing negative impact as people move from first treatment to multiple treatments.

Previous studies [@b5],[@b14] have demonstrated a correlation between lower QoL scores using the NEI--VFQ 25 and loss of vision in diabetic macular oedema and proliferative diabetic retinopathy.

This study does have some limitations:

The insensitivity of the EQ--5D for visual disorders is well established [@b15],[@b16].Furthermore, mapping NEI--VFQ 25 scores to EQ--5D utilities has been shown to provide low predictive power, suggesting an inability of the EQ--5D to discriminate vision-related activities [@b17].

However, the EQ--5D is an important tool that is used to determine cost-effectiveness for appraisals of new pathways and treatments by the National Institute for Health and Clinical Excellence (NICE) in England. We believe that, in such appraisals, data from both eyes should be used.

A recent review [@b18] found a stronger correlation between health state utility values (HSUVs) and better-seeing eye VA compared with worse-seeing eye VA. Our study has demonstrated that the VA in both eyes needs to be considered and is the first study to report a correlation between VA in the better- and worse-seeing eyes in diabetic macular oedema.

We would recommend that a weighted VA measure of 0.75 in the better and 0.25 in the worse eye, or 0.60 in the better and 0.40 in the worse eye is used in future diabetic macular oedema trials because this study has demonstrated that the most information can be provided by taking into account vision in both eyes when determining the effect on quality of life.
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